Skip to content

The Adjunctive Use of Lavender and Peppermint Essential Oils

The Adjunctive Use of Lavender and Peppermint Essential Oils to Manage Nausea, Pain, and Anxiety in an Adult Orthopedic Population

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04934969
Acronym
aromatherapy
Enrollment
3
Registered
2021-06-22
Start date
2021-07-30
Completion date
2023-08-01
Last updated
2024-04-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Joint Diseases

Brief summary

This study will use passive inhalation of lavender for discomfort, anxiety and peppermint for nausea following joint replacement and spine surgery

Detailed description

Following review of records for eligibility and consent obtained during pre op visit subjects will be enrolled in study post op they will validate desire to participate and chose to inhale (2 drops of essential oil on cotton ball in a plastic bag) lavender for discomfort or anxiety or peppermint for GI distress Visual analogue scales will be used to rate discomfort , anxiety and nausea

Interventions

DIETARY_SUPPLEMENTAdjunctive use of lavender and peppermint essential oils

passive inhalation aromatherapy following joint surgery

Sponsors

University Hospitals Cleveland Medical Center
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Intervention model description

feasibility of using essential oils post joint replacement surgery and trends toward relief of symptoms

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

\- elective joint replacement able to read and speak English and describe study procedures

Exclusion criteria

pregnancy * unable to smell, sensitivity to fragrances asthma or breathing problems have smoke or vaped in last 2 weeks if atrial fibrillation history no peppermint uncontrolled hypertension above 160/100 non employees of UH or students of CWRU

Design outcomes

Primary

MeasureTime frameDescription
discomfort, anxiety, or GI distresstotal of 90 minutesvisual analog sale

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026